Phase II evaluation of PTK787 [vatalanib], an oral vascular endothelial growth factor inhibitor, in patients with non-metastatic androgen independent prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Vatalanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Feb 2010 Actual end date (April 2008) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.